Sep 2021
DDR and PARPi BluePrint documents have been developed under the guidance of a Steering Committee with expertise in the field of DDR and PARP inhibition (PARPi).
These BluePrints are a reference guide to key aspects of PARPi and DDR and their role in oncology.
A variety of topics are covered, including the role of DDR in oncology, synthetic lethality, use of PARPi in oncology, efficacy and safety of currently approved PARP inhibitors, and the role of combination therapy with PARPi.
AstraZeneca and Tesaro.
AstraZeneca, Clovis, Cristal Therapeutics, Pfizer, Roche and Seattle Genetics.
AstraZeneca, Clovis, Pfizer, Roche and Tesaro.
Artios Pharma Ltd.
AstraZeneca, Apera, Clovis, MSD, Nucana, Novartis, Roche, Sierra Oncology and Tesaro.
AstraZeneca.
AstraZeneca, Amgen, Novartis, Pfizer and Roche.
Duration MIN
Downloadable resources Yes
DOWNLOAD DDR BLUEPRINT
DOWNLOAD PARPi BLUEPRINT
Language(s)
Video
Two emerging and two established targets
Downloadable 
4 MIN
Dec 2024 
Publication
Announcing the publication of survey results
Downloadable
10 MIN
Dec 2024 
Video
An expert overview of the EMERALD subgroup analysis
Downloadable
4 MIN
Dec 2024 
Video
Managing patients with nccRCC: guidelines, recommendations, and best practice
Downloadable
4 MIN
Dec 2024 
Micro learning
Risk factors, diagnostic tools and treatment options for different patient groups
Downloadable
4 MIN
Dec 2024 
Conference update
Exploring emerging treatment strategies presented at SABCS 2024
Downloadable
5 MIN
Dec 2024
